
A manager's guide to helping grieving employees
In the UK, it is currently Dying Matters Awareness Week. Grief—and the impact of death and loss—is something that nearly all of us will experience at some point in our working lives. Despite this, many workplaces are not equipped to have these tricky conversations and are unsure how to best support their staff with their mental well-being while grieving. At This Can Happen, we conducted an in-depth, two-stage research project into how workplaces are supporting employees with grief— the Grief In The Workplace Report —and the findings are eye-opening.
We found that 87% of respondents with lived experience felt grief had impacted their mental well-being, yet 46% felt that they did not have enough time to grieve and 51% did not feel supported by their organization. This is a critical issue for managers and leaders in the workplace that is impacting not only employee mental well-being, but also the ability for staff to perform at work. In fact, 76% said since returning to work they had not received any communications from managers or leadership in relation to their grief, and 76% also said they felt their loss had affected their performance in their immediate return to work.
So, how can employers help? Here are five ways.
1. Break the taboo in speaking about grief and bereavement
These conversations should be led from the top-down to tackle stigma and build psychological safety in the workplace. This is the responsibility of both leadership and line managers. For example, if members of leadership have lived experience of grief and loss, consider how personal storytelling from these individuals could have a transformative impact on staff likelihood to share their own challenges. This could take the form of an internal blog, a panel discussion, or even an update in a company meeting. Line managers can then pick up on this note and continue these conversations in catch-ups with line reports, encouraging open and honest conversation about mental well-being to build trust, so that employees know that they can immediately go to their manager when they need support.
2. Put the right support in place
Providing the right resources—and ensuring that staff know where to find them—is crucial. Our research shows that this is currently an area in which businesses are struggling, with 37% of respondents unsure about what resources were currently available to support them with grief. Make sure that you have a comprehensive Employee Assistance Programme (EAP) in place, which is a confidential service that supports staff—and sometimes their family members—with their health, including counseling, referrals, and expert advice. Consider creating worksheets with tips and advice about living through bereavement, along with helpful links that employees might want to explore for further reading or conversations. Finally, ensure that line managers are fully trained in having these conversations in the workplace, and understanding what resources your organization has in place, so that they can signpost staff correctly and efficiently.
3. Be open, empathetic, and human in your approach
This might sound like an obvious one, but it's not; so many leaders and managers approach grief and bereavement from a policy-led perspective, or avoid the conversation altogether because they are afraid of saying what could be perceived as the 'wrong thing.' Some 64% of respondents in our research had not heard their managers talking openly about bereavement. Take the time to understand what employees are thinking and feeling in terms of their grief, and what they need right now—keeping in mind that grief is not one linear path forward, but rather a journey that's filled with peaks and troughs over time. This can be heightened around key moments such as anniversaries and birthdays. Keep the lines of communication open to understand what employees need at any given moment, and how you as an employer can really make a tangible impact in the support you offer.
4. Give employees experiencing grief both space and flexibility at work
Make sure employees who have uttered a loss know that you as an employer or line manager are there for them to speak to if they need it, but also give them the time and space to process their grief as needed. As much as you can within your workplace and industry, offer flexible working arrangements to bereaved staff. The thought of going into the office following a bereavement can sometimes be an overwhelming prospect; try to understand the impacts of grief in the short-, medium- and long-term, and understand where staff might benefit from flexible working arrangements.
5. Consider how you can provide ongoing support
For example, if resources allow, consider meeting with a psychologist to explain how to set up bereavement support, and ensure that this is baked into the heart of an organization, rather than sitting solely in a policy. From here, speak to staff and understand if there's anything further that they would like to set up from a grassroots perspective. A lot of powerful work that we have seen in this space has been created and run organically by employees—lunch-and-learn sessions on lived experience with grief or quarterly drop-in 'grief cafés,' for instance.
These are all thought-starters on how best to support employees experiencing grief. The most important thing that you can do as a leader or manager is to be kind, empathetic and understanding to the challenges that these team members are facing, and listen with an open ear around how best to support them. You'll soon see the benefits of this, not just on employee mental well-being, but in terms of presenteeism and productivity as well.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
20 minutes ago
- Medscape
Mavacamten Showing Real-World Success in Treating oHCM
MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said at the recent British Cardiovascular Society Annual Conference 2025. William Jenkins, a consultant cardiologist at the Royal Infirmary of Edinburgh, said that real world outcomes mirror those from clinical trials, including EXPLORER and VALOR-HCM. High Rates of Symptom Improvement Notably, data from three UK centres showed that about 70%-80% of patients experienced symptomatic improvement with mavacamten treatment. In addition, 90% saw a 30mmHg drop in the left ventricular outflow tract (LVOT) gradient – considered a significant reduction in obstruction. William Jenkins Although patients initially required 'very intense echocardiographic surveillance', Jenkins said 'it gets much easier' after the first few months of treatment. 'I think our reliance upon echocardiography will probably reduce as we get more experience with this,' he told Medscape News UK . A First-in-Class Therapy Mavacamten, a cardiac myosin inhibitor, is the first drug of its kind. It works by normalising contractility, reducing dynamic LVOT obstruction, and improving cardiac filling pressures in people with HCM. 'HCM is something that develops over decades,' Jenkins said. 'You can develop symptoms early, but you can have those symptoms for a really long time before you go on to develop other things like abnormal heart rhythms, heart failure, or dying suddenly.' He added that although oHCM is considered rare, many patients could benefit from treatment. Managing HCM still falls within general cardiology in some centres, Jenkins noted, raising concerns that patients may not be reviewed as frequently as needed. 'People live with it for years and years — if not decades — before they develop any of the end stage features of HCM,' Jenkins said. 'They can become very adapted to their symptoms.' Patient Advocacy and Experience Hypertrophic cardiomyopathy affects around 1 in 500 people in the UK and US, with about two thirds of cases involving obstruction. Katharine McIntosh, head of research and policy at Cardiomyopathy UK, told Medscape News UK that mavacamten had been a 'cause for excitement' among patients. 'It's the first big cardiomyopathy-specific drug.' McIntosh expressed frustration at the slow rollout of the drug, which was recommended for NHS use in England and Wales in 2023 and in Scotland in 2024. 'It's at the point now where one would have thought that everyone who should be on it would be getting onto it. But that's just not been the case,' she said. A recent Cardiomyopathy UK survey found that patients who accessed mavacamten were 'very positive' about its effects. Respondents described it as 'life changing' and felt like they had been given their lives back, McIntosh said. Challenges Facing Widespread Use One barrier is that mavacamten must be prescribed and monitored by specialists experienced in treating cardiomyopathies – resources not available at all centres. Prescribing guidance states that patients require echocardiography before and at regular intervals after starting treatment. Genetic testing for Cytochrome P450 (CYP) 2C19 (CYP2C19) is also needed to guide dosing. Long-Term Outlook Jenkins said that three key issues must be considered before prescribing mavacamten: Close early monitoring is needed, as the drug can cause left ventricular systolic dysfunction. CYP2C19-related drug interactions require pharmacy input. Counselling is essential due to potential foetal toxicity risks. 'Most people tolerate this [drug] very well', he said. After the initial 12-week period, follow-up can be reduced to every 3-6 months. 'This is an indefinite medication for a lot of people' Jenkins said. However, with an estimated annual cost of almost £14,000 per patient, he stressed the need for careful initial use. 'Right now, the indication is for symptomatic, severe LVOT obstruction,' he said. However, 'there's no reason in the long-term why this shouldn't become first-line'. Whether mavacamten offers benefit for oHCM patients without obstruction remains unclear. Jenkins has acted as a consultant to BMS and AstraZeneca. McIntosh had no conflicts of interest to disclose.
Yahoo
2 hours ago
- Yahoo
Toxic 'forever chemical' showing up in European food and wine
A team of researchers has found "alarmingly high" levels of trifluoroacetic acid (TFA), a so-called forever chemical, in dozens of organic and non-organic pastas, baked goods and breakfast cereals from Europe, as well as in wine. "In conventional grain products, the average levels were so high that a health risk to children can no longer be ruled out," said Helmut Burtscher-Schaden, an environmental chemist part of the Brussels-based Pesticide Action Network (PAN) Europe, which describes TFA as a "product of PFAS pesticides and industrial chemicals." Forever chemicals, also known as PFAS, are thousands of long-lasting substances used in household and everyday products since the middle of the 20th century but which have been found to be difficult to remove from the environment and from human bodies. The latest research points to 'widespread contamination from PFAS (per- and poly-fluoroalkyl substances) pesticides," PAN Europe said, warning that TFA tends to build up in water and farmland. The amount of TFA in the food items was found to be three times that recorded in a similar study eight years ago, according to PAN Europe, which in April warned of "dramatic rise" of TFA in wine. In a report covering wines from Austria, Belgium, Croatia, France, Germany, Greece, Hungary, Italy, Luxembourg and Spain, PAN Europe found that while pre-1988 vintages do not contain any such contamination, there has been a "sharp increase" in pesticide and chemical residues in wine bottled since 2010. Such a "steep accumulation" should be "a red flag that calls for decisive action," according to Michael Müller, a professor of pharmaceutical and medicinal chemistry at the University of Freiburg. The European Chemicals Agency has warned that TFA "may cause harm to the unborn child" and "may impair fertility."


Fox News
2 hours ago
- Fox News
First-known puberty blocker patient says 'insulting' youth gender movement makes mockery of true dysphoria
The first known patient to take puberty blockers to treat gender dysphoria sharply rebuked the modern youth gender identity movement as "insulting" in a podcast interview with the New York Times published last week. The Times spoke with "FG," a patient in adolescent transgender medicine from the Netherlands, who was the first known person given puberty blockers at 13years-old in the 1980s to stop female development. "FG" explained dealing with anger issues as a child and feeling uncomfortable living as a girl. The fear of going through puberty led the teen to express suicidal thoughts in a letter and eventually seek out medical treatment to stop normal development, as well as cross-sex hormones and gender reassignment surgery later on. Now, living as a man decades later with no regrets, "FG" believes puberty blockers "saved my life." Despite being a proponent of these medical interventions, "FG" was not supportive of the modern gender diversity movement. "So many of the young people now want to visibly challenge the binary," New York Times reporter Azeen Ghorayshi told "FG," asking, "What do you make of that? And what do you make of what that means for getting the medical treatment that you pioneered?" "I find that it's gone — it's gone a bit extreme to the other side," "FG" replied. "So it makes a laughingstock of what it's really about. Or at least, it seems to be a fashion statement nowadays." "FG" equated the current gender climate to other youth rebellion movements of the past where young people forged their identities "to stand out," saying gender seemed to be another forum for that today. "And for the group that is pure, like proper transsexuals, this flirting with pronouns and gender identity — it's insulting," "FG" continued. "FG", who works in the medical field and asked to stay anonymous out of a desperate desire to fit in as a man, said it seemed like young people now treat their gender identity as a fad. "Because like I said, we spend all our time trying to just fit in or be able to live the life that we feel we should have had. And it's not a great help when you've got people shouting from the barricades and trying to give you a different position, a third sex or whatever, and then talk about things that we don't want you to talk about, so that they can identify you," "FG" added. "I don't take a lot of these people that seriously, because it does seem to be a bit of a fashion statement." Shortly after taking office for his second term, President Donald Trump signed an executive order cutting off federal funding for institutions who engage in "chemical and surgical" sex-change procedures for minors. "Across the country today, medical professionals are maiming and sterilizing a growing number of impressionable children under the radical and false claim that adults can change a child's sex through a series of irreversible medical interventions," the order, titled "Protecting Children from Chemical and Surgical Mutilation," states. "This dangerous trend will be a stain on our Nation's history, and it must end." A number of hospitals nationwide challenged the order earlier this year, with some vowing to continue providing these medical interventions for minors.